Intelligent Treatment Selection System for Major Depressive Disorder (MDD)

THE PROBLEMS

- Psychiatrist and practitioner are having difficulties in prescribing the right and effective anti-depressant to a patient with MDD.
- Trial and error is normally done by prescribing one of the 20 anti-depressant available.
- Patient’s treatment management will take longer time and recovery is therefore delayed.

THE BENEFITS

- Patient’s treatment management will be done by an intelligent system that will evaluate the patient’s condition
- Medication prescription will be based on the evaluation, customary to the patient’s need
- Evaluation time up to prescription of medication will just take 15 minutes
- 95% effectiveness of the medication prescribed, no trial and error is required
- Increase patient’s chances of recovery and quality of life.

SNAPSHOT

The diagnosis and treatment management for Major Depressive Disorder (MDD) has always been a problem among psychiatrists and practitioners. It is a challenge to choose and prescribe a patient with MDD with a suitable anti-depressant that falls under the Selective Serotonin Re-uptake Inhibitors (SSRIs) for it to be effective the first time being prescribed. There are about a pool of 20 different anti-depressant available and normally patients will be prescribed with one and after a certain period of time, patients will have to visit the psychiatrist to evaluate the effectiveness of the medication. The cycle continues until an effective one is found.

COMMERCIAL OPPORTUNITY

This innovative product is an automated system, an application/software that can assist physicians and psychiatrists in performing the diagnosis for Major Depressive Disorder (MDD) patients up to the prescription of suitable and effective medication for the patients.

In South East Asia, the number of MDD patients are increasing and according to a report by the Ministry of Health, Malaysia, by the year 2020, MDD is projected to be the second largest contributor to the global burden of disease, after heart disease. Depression and MDD incur substantial public health and economic costs. Therefore, a more effective patients’ management system has to be developed in order to reduce the incidence.

The market potential for this innovative product will be the psychiatrists and the hospitals (private and public) which offer diagnosis and treatment program for MDD patients.

This innovative product will be able to be commercialised via a licensing deal.

INTELLECTUAL PROPERTY

The invention will be protected by a Malaysian patent and copyright.

WHAT’S NEXT?

A working prototype is available and further enhancement and testing will be required and the product is open for licensing deal.

CONTACT

info@platcomventures.com
03-83193116

www.platcomventures.com

PROJECT CODE: 156

© 2015 PlaTCOM Ventures. All rights reserved.